Biosergen AB (OSTO:BIOSGN) Total Operating Expense: kr40.86 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:BIOSGN Biosergen AB OSTO:BIOSGN
18 GF Score
Price kr6.00
View Full Analysis

What is Biosergen AB Total Operating Expense?

Biosergen AB OSTO:BIOSGN 18 Total Operating Expense is kr40.86 Mil as of Dec. 2025. GuruFocus rates OSTO:BIOSGN with a GF Score™ of 18/100.

Biosergen AB's Total Operating Expense for the three months ended in Dec. 2025 was kr12.49 Mil. Biosergen AB's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was kr40.86 Mil.

Biosergen AB Total Operating Expense Related Terms

Biosergen AB Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Biosergen AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosergen AB Total Operating Expense Chart

Biosergen AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 33.90 34.52 27.18 19.29 38.04

Biosergen AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.33 5.14 11.04 12.19 12.49
OSTO:BIOSGN
18GF Score
Biosergen AB OSTO:BIOSGN
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosergen AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr40.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of kr40.86 Mil mean?
Biosergen AB (OSTO:BIOSGN) has a Total Operating Expense of kr40.86 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Biosergen AB and its competitors.
Is Biosergen AB's Total Operating Expense too high?
Biosergen AB's current Total Operating Expense is kr40.86 Mil. Overall, Biosergen AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biosergen AB's Total Operating Expense compare to VRTX and REGN?
Biosergen AB's Total Operating Expense of kr40.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Biosergen AB and its competitors. Biosergen AB's current Total Operating Expense is kr40.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosergen AB stock overvalued right now?
Biosergen AB (OSTO:BIOSGN) has a current Total Operating Expense of kr40.86 Mil. The current Total Operating Expense is kr40.86 Mil. Biosergen AB's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Biosergen AB (OSTO:BIOSGN), the current Total Operating Expense is kr40.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biosergen AB Business Description

Address Fogdevreten 2, Solna, SWE, 17165
Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen' s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.
18GF Score

Get the complete analysis for OSTO:BIOSGN

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.00
Price